Key Executive Takeaways
- AI-validated digital biomarkers from Verge Genomics, Emerald Innovations, ActiGraph, and Modality.AI show disease progression in ALS within just 8 weeks—before treatment even begins.
- VRG50635 Phase 1b trial integrates real-world, high-frequency digital monitoring across mobility, speech, sleep, and respiration functions.
- Signals a new paradigm in neuro clinical trials, accelerating timelines and precision in patient-centric drug evaluation for ALS.
Digital Biomarkers Show Disease Progression—Before Drug Intervention
Verge Genomics has demonstrated that digital clinical biomarkers can detect statistically significant ALS disease progression in as little as eight weeks, even before drug administration begins. This finding came from the pre-treatment run-in period of the company’s Phase 1b proof-of-concept trial evaluating VRG50635, a PIKfyve inhibitor targeting both sporadic and familial ALS. The study measured key ALS-affected functions—mobility, sleep, respiration, and speech—leveraging touchless and wearable technologies. These early, objective signals are likely to optimize patient stratification and dosing decisions moving forward.
AI + Sensor Collaboration Delivers Real-World, Multimodal Data
To collect robust, real-world data, Verge partnered with:
- Emerald Innovations: AI/ML-based wireless sensors captured walking speed, turning in bed, sleep patterns, and respiratory variability.
- ActiGraph: Wearables tracked activity levels and sleep metrics.
- Modality.AI: An AI-driven platform assessed articulation and phonation via a speech task administered through web-based tools.
These technologies minimized patient burden while maximizing functional precision—setting a new standard for tech-enabled ALS trials.
VRG50635 ALS Trial Completion on Track for Efficacy Results
With enrollment completed in August 2024, Verge Genomics’ VRG50635 trial remains on schedule to report efficacy and safety outcomes by the second half of 2025. This is among the first ALS trials to integrate such comprehensive digital biomarker tracking from pre-dose phases, offering critical insights into early disease trajectory and therapeutic responsiveness. This approach aims to reduce trial sizes, shorten durations, and improve endpoint sensitivity for faster decision-making.
Shaping the Future of Neurodegeneration Trials with AI
Verge Genomics’ CONVERGE® platform—a proprietary human data and AI engine—is central to the company’s strategy of transforming complex disease drug discovery. Their tech-enabled clinical design in ALS demonstrates how next-generation tools can reshape not only how drugs are discovered but also how they’re tested. Leaders from Emerald Innovations, ActiGraph, and Modality.AI echoed the broader industry shift toward continuous, home-based, patient-centric evaluation, especially for diseases with fast progression and high unmet need like ALS.
About Verge Genomics
Verge Genomics is a clinical-stage, AI-powered biotech company using human data and machine learning to accelerate drug discovery. With a growing pipeline in ALS and obesity, Verge leverages one of the industry’s most comprehensive multi-omic patient datasets. Learn more at www.vergegenomics.com
By
